For original article click here

Display options

Format AbstractPubMedPMID

Abstract

At present, the prevalence of Alzheimer’s disease, a devastating neurodegenerative disorder, is increasing. Although the mechanism of the underlying pathology is not fully uncovered, in the last years, there has been significant progress in its understanding. This includes: Progressive deposition of amyloid β-peptides in amyloid plaques and hyperphosphorylated tau protein in intracellular as neurofibrillary tangles; neuronal loss; and impaired glucose metabolism. Due to a lack of effective prevention and treatment strategy, emerging evidence suggests that dietary and metabolic interventions could potentially target these issues. The ketogenic diet is a very high-fat, low-carbohydrate diet, which has a fasting-like effect bringing the body into a state of ketosis. The presence of ketone bodies has a neuroprotective impact on aging brain cells. Moreover, their production may enhance mitochondrial function, reduce the expression of inflammatory and apoptotic mediators. Thus, it has gained interest as a potential therapy for neurodegenerative disorders like Alzheimer’s disease. This review aims to examine the role of the ketogenic diet in Alzheimer’s disease progression and to outline specific aspects of the nutritional profile providing a rationale for the implementation of dietary interventions as a therapeutic strategy for Alzheimer’s disease.

Keywords: Alzheimer’s disease; amyloid; dementia; ketogenic diet; ketone bodies therapy; neuroinflammation; tau protein.

Conflict of interest statement

Figures

Figure 1

Hypothesized mechanisms through which ketogenic…

Figure 1

Hypothesized mechanisms through which ketogenic diet (KD) influence Alzheimer’s disease (AD) development. ↓—decreased;…

Figure 1

Hypothesized mechanisms through which ketogenic diet (KD) influence Alzheimer’s disease (AD) development. ↓—decreased; ↑—increased. Based on Reference [7].

Figure 2

Hypothetical pathways leading to the…

Figure 2

Hypothetical pathways leading to the neuroprotective action of KD (based on References [50,108]).…

Figure 2

Hypothetical pathways leading to the neuroprotective action of KD (based on References [50,108]). FA—fatty acids; GABA—γ-aminobutyric acid; PCr:Cr—phosphocreatine:creatine ratio; ROS—reactive oxygen species; UCP—uncoupling proteins; increase (↑) or decrease (↓)—arrows indicate the direction of the relationship between variables.

See this image and copyright information in PMC

Similar articles

• The ketogenic diet as a potential treatment and prevention strategy for Alzheimer’s disease.

  Broom GM, Shaw IC, Rucklidge JJ. Broom GM, et al. Nutrition. 2019 Apr;60:118-121. doi: 10.1016/j.nut.2018.10.003. Epub 2018 Oct 10. Nutrition. 2019. PMID: 30554068 Review.

• A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer’s disease.

  Kashiwaya Y, Bergman C, Lee JH, Wan R, King MT, Mughal MR, Okun E, Clarke K, Mattson MP, Veech RL. Kashiwaya Y, et al. Neurobiol Aging. 2013 Jun;34(6):1530-9. doi: 10.1016/j.neurobiolaging.2012.11.023. Epub 2012 Dec 29. Neurobiol Aging. 2013. PMID: 23276384 Free PMC article.

• Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer’s pathology.

  Brownlow ML, Benner L, D’Agostino D, Gordon MN, Morgan D. Brownlow ML, et al. PLoS One. 2013 Sep 12;8(9):e75713. doi: 10.1371/journal.pone.0075713. eCollection 2013. PLoS One. 2013. PMID: 24069439 Free PMC article.

• Triheptanoin supplementation to ketogenic diet curbs cognitive impairment in APP/PS1 mice used as a model of familial Alzheimer’s disease.

  Aso E, Semakova J, Joda L, Semak V, Halbaut L, Calpena A, Escolano C, Perales JC, Ferrer I. Aso E, et al. Curr Alzheimer Res. 2013 Mar;10(3):290-7. doi: 10.2174/15672050112099990128. Curr Alzheimer Res. 2013. PMID: 23131121

• Amyloid-induced neurofibrillary tangle formation in Alzheimer’s disease: insight from transgenic mouse and tissue-culture models.

  Götz J, Schild A, Hoerndli F, Pennanen L. Götz J, et al. Int J Dev Neurosci. 2004 Nov;22(7):453-65. doi: 10.1016/j.ijdevneu.2004.07.013. Int J Dev Neurosci. 2004. PMID: 15465275 Review.

See all similar articles

Cited by 10 articles

• Does Diet Have a Role in the Treatment of Alzheimer’s Disease?

  Thelen M, Brown-Borg HM. Thelen M, et al. Front Aging Neurosci. 2020 Dec 23;12:617071. doi: 10.3389/fnagi.2020.617071. eCollection 2020. Front Aging Neurosci. 2020. PMID: 33424583 Free PMC article. Review.

• Nootropic Effects of C. melo and C. lanatus seed extracts.

  Wahid S, Alqahtani A, Khan RA. Wahid S, et al. Biomed Res Int. 2020 Dec 9;2020:8823038. doi: 10.1155/2020/8823038. eCollection 2020. Biomed Res Int. 2020. PMID: 33376745 Free PMC article.

• Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease.

  Toniolo S, Sen A, Husain M. Toniolo S, et al. Int J Mol Sci. 2020 Dec 7;21(23):9318. doi: 10.3390/ijms21239318. Int J Mol Sci. 2020. PMID: 33297460 Free PMC article. Review.

• Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases.

  Jensen NJ, Wodschow HZ, Nilsson M, Rungby J. Jensen NJ, et al. Int J Mol Sci. 2020 Nov 20;21(22):8767. doi: 10.3390/ijms21228767. Int J Mol Sci. 2020. PMID: 33233502 Free PMC article. Review.

• Proteomics for Studying the Effects of Ketogenic Diet Against Lithium Chloride/Pilocarpine Induced Epilepsy in Rats.

  Zheng YQ, Jin MF, Suo GH, Wu YJ, Sun YX, Ni H. Zheng YQ, et al. Front Neurosci. 2020 Sep 29;14:562853. doi: 10.3389/fnins.2020.562853. eCollection 2020. Front Neurosci. 2020. PMID: 33132826 Free PMC article.

See all “Cited by” articles

References

1. 1. Patterson C. The World Alzheimer Report 2018: The State of the Art of Dementia Research: New Frontiers. Alzheimer’s Disease International (ADI); London, UK: Sep, 2018. [(accessed on 5 August 2019)]. Available online: https://www.alz.co.uk/research/world-report-2018.
2. 1. Kelley B.J., Petersen R.C. Alzheimer’s disease and mild cognitive impairment. Neurol. Clin. 2007;25:577–609. doi: 10.1016/j.ncl.2007.03.008. – DOI – PMC – PubMed
3. 1. Lange K.W., Lange K.M., Makulska-Gertruda E., Nakamura Y., Reissmann A., Kanaya S., Hauser J. Ketogenic diets and Alzheimer’s disease. Food Sci. Hum. Wellness. 2017;6:1–9. doi: 10.1016/j.fshw.2016.10.003. – DOI
4. 1. Serrano-Pozo A., Frosch M.P., Masliah E., Hyman B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011;1:a006189. doi: 10.1101/cshperspect.a006189. – DOI – PMC – PubMed
5. 1. Swerdlow R.H. Brain aging, Alzheimer’s disease, and mitochondria. Biochim. Biophys. Acta. 2011;1812:1630–1639. doi: 10.1016/j.bbadis.2011.08.012. – DOI – PMC – PubMed

Publication types

• Actions

MeSH terms

• Actions

• Actions

• Actions

• Actions

• Actions

• Actions

• Actions

• Actions

• Actions

• Actions

• Actions

Substances

• Actions

• Actions

For original article click here